Wilms' Tumor 1 Gene Expression Using a Standardized European LeukemiaNet-Certified Assay Compared to Other Methods for Detection of Minimal Residual Disease in Myelodysplastic Syndrome and Acute Myelogenous Leukemia after Allogeneic Blood Stem Cell Transplantation

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Christina RautenbergThomas Schroeder

Abstract

Overexpression of the Wilms' tumor 1 (WT1) gene is informative in many patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) and is measurable in peripheral blood (PB). Despite these advantages, WT1 has not broadly been established as a marker for minimal residual disease (MRD) monitoring after allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to limited patient numbers, differing sample sources, and nonstandardized in-house methods. To estimate the value of WT1 as an MRD marker, we serially quantified PB WT1 expression using a standardized European LeukemiaNet-certified assay in 59 patients with AML and MDS after allo-HSCT. We compared its performance with routine methods such as chimerism, XY-fluorescence in situ hybridization (FISH), disease-specific cytogenetic, and molecular analyses, which were accessible in 100%, 34%, 68%, and 37%, respectively. Twenty-four patients (41%) relapsed within a median of 126 days after allo-HSCT, and 20 of them showed at least 1 elevated WT1 value above the validated cutoff. The other 35 patients (59%) remained in complete remission, and only 1 patient had a transient increase in WT1 expression. This reflects a sensitivity of 83% and a specificity...Continue Reading

References

Jun 5, 2004·Acta Haematologica·Susanne SchnittgerTorsten Haferlach
Jun 30, 2004·Leukemia & Lymphoma·Hiroyasu OgawaHiroya Tamaki
Apr 2, 2005·British Journal of Haematology·Charles CraddockDavid Grimwade
Nov 15, 2007·Cancer·Wolfgang KernSusanne Schnittger
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CilloniDavid Grimwade
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Dec 15, 2011·Blood·Christoph SchmidUNKNOWN Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Jan 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Ulrike BacherMichael R Bishop
Jun 27, 2013·Nature Reviews. Clinical Oncology·Christopher S Hourigan, Judith E Karp
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lars BullingerHartmut Döhner

❮ Previous
Next ❯

Citations

Jul 20, 2019·Expert Review of Hematology·Guido KobbeUlrich Germing
Jan 11, 2019·International Journal of Molecular Sciences·Christina RautenbergThomas Schroeder
Dec 7, 2019·Hematology·Jacqueline CloosRichard Dillon
Aug 18, 2018·Bone Marrow Transplantation·Marco LadettoPeter Bader
Nov 14, 2019·Blood Cancer Journal·Christina RautenbergThomas Schroeder
Oct 6, 2020·Frontiers in Immunology·Sophia Chen, Robert Zeiser
May 29, 2021·Leukemia·Uwe PlatzbeckerThomas Prebet
Sep 18, 2021·Current Opinion in Hematology·Anne E Austin, Michael Byrne

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.